Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (NASDAQ: SLDB) has announced the granting of 43,374 restricted stock units (RSUs) to three newly hired employees. The RSUs are structured with a four-year vesting schedule, with 25% vesting annually on each grant date anniversary. The equity awards, issued under the Company's 2024 Inducement Stock Incentive Plan, are contingent upon continued employment through each vesting date. This compensation package was designed as an inducement for employment and complies with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (NASDAQ: SLDB) ha annunciato l'assegnazione di 43.374 unità azionarie riservate (RSU) a tre nuovi dipendenti. Le RSU sono strutturate con un piano di maturazione di quattro anni, con il 25% che matura annualmente in occasione dell'anniversario della data di concessione. I premi azionari, emessi nell'ambito del Piano di Incentivazione Azionaria per Induzione 2024 della Società, sono subordinati al mantenimento dell'impiego fino a ciascuna data di maturazione. Questo pacchetto retributivo è stato progettato come incentivo per l'assunzione e rispetta la Regola di Quotazione Nasdaq 5635(c)(4).
Solid Biosciences (NASDAQ: SLDB) ha anunciado la concesión de 43,374 unidades de acciones restringidas (RSUs) a tres empleados recién contratados. Las RSUs están estructuradas con un calendario de adquisición de cuatro años, con un 25% que se adquiere anualmente en el aniversario de la fecha de concesión. Los premios en acciones, emitidos bajo el Plan de Incentivos de Acciones por Inducción 2024 de la Compañía, están sujetos a la continua empleabilidad hasta cada fecha de adquisición. Este paquete de compensación fue diseñado como un incentivo para el empleo y cumple con la Regla de Cotización 5635(c)(4) de Nasdaq.
솔리드 바이오사이언스 (NASDAQ: SLDB)는 세 명의 신입 직원에게 43,374개의 제한 주식 단위(RSU)를 부여했다고 발표했습니다. RSU는 4년의 분할 일정으로 구성되어 있으며, 매년 부여일 기념일에 25%가 분할됩니다. 이 주식 보상은 회사의 2024 유인 주식 인센티브 계획에 따라 발행되며, 각 분할일까지 계속 근무해야 합니다. 이 보상 패키지는 고용 유인을 위해 설계되었으며, 나스닥 상장 규칙 5635(c)(4)를 준수합니다.
Solid Biosciences (NASDAQ: SLDB) a annoncé l'octroi de 43 374 unités d'actions restreintes (RSU) à trois nouveaux employés. Les RSU sont structurées selon un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition chaque année à l'anniversaire de la date d'octroi. Les récompenses en actions, émises dans le cadre du Plan d'Incentive d'Actions par Induction 2024 de l'entreprise, sont conditionnées à un emploi continu jusqu'à chaque date d'acquisition. Ce paquet de compensation a été conçu comme un incitatif à l'emploi et est conforme à la règle de cotation Nasdaq 5635(c)(4).
Solid Biosciences (NASDAQ: SLDB) hat die Gewährung von 43.374 beschränkten Aktieneinheiten (RSUs) an drei neu eingestellte Mitarbeiter bekannt gegeben. Die RSUs sind mit einem vierjährigen Vesting-Plan strukturiert, wobei 25 % jährlich am Jahrestag des Gewährungsdatums fällig werden. Die Aktienvergütungen, die im Rahmen des 2024 Inducement Stock Incentive Plans des Unternehmens ausgegeben werden, sind an die fortdauernde Beschäftigung bis zu jedem Vesting-Datum gebunden. Dieses Vergütungspaket wurde als Anreiz für die Beschäftigung gestaltet und entspricht der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted stock units (“RSUs”) to three newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
How many restricted stock units (RSUs) did Solid Biosciences (SLDB) grant to new employees in April 2025?
What is the vesting schedule for SLDB's April 2025 RSU grants?
Under which plan were SLDB's April 2025 RSU grants issued?
What conditions must be met for the SLDB RSU grants to vest?
